Preferred Label : Podentamig;
NCIt synonyms : BCMA/CD3e TriTAC HPN217; BCMA/CD3e-specific TriTAC HPN217; TriTAC HPN217; Anti-BCMA/CD3e TriTAC HPN217; BCMA/CD3 Tri-specific T-cell Activating Construct HPN217; BCMA/CD3e Tri-specific T-cell Activating Construct HPN217;
NCIt definition : A recombinant antibody derivative composed of tri-specific T-cell activating construct
(TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation
antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes,
and albumin, with potential immunostimulating and antineoplastic activities. Upon
administration, podentamig targets and binds to BCMA on tumor cells and CD3e on cytotoxic
T-lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together,
which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding
domain targets and binds to serum albumin, thereby extending the serum half-life of
podentamig. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF),
is overexpressed on malignant plasma cells and plays a key role in plasma cell survival.;
UNII : ZT35532VPU;
CAS number : 2851863-52-8;
Molecule name : HPN-217; HPN 217;
NCI Metathesaurus CUI : CL1405854;
Origin ID : C171631;
UMLS CUI : C5417875;
Semantic type(s)
- concept_is_in_subset
- has_target
